MSHLSacituzumab govitecan Powder For Solution For Infusion 180 mg
1) Treatment of unresectable locally advanced or metastatic triple negative breast cancer in patients who have received two or more prior systemic therapies, at least one of them for metastatic disease.
2) Treatment of patients with unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.